申请人:Meissner Robert S.
公开号:US20090088458A1
公开(公告)日:2009-04-02
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
结构式I的化合物以组织选择性的方式调节雄激素受体(AR)。这些化合物可用于增强肌肉松弛并治疗由雄激素缺乏引起或可通过雄激素治疗改善的疾病,包括骨质疏松症、骨质疏松、糖皮质激素诱导的骨质疏松、牙周病、骨折、骨重建手术后的骨损伤、肌肉萎缩、衰弱、皮肤老化、男性性腺功能减退、女性绝经后症状、动脉粥样硬化、高胆固醇血症、高脂血症、肥胖症、再生障碍性贫血和其他造血系统疾病、炎性关节炎和关节修复、艾滋病消耗综合征、前列腺癌、良性前列腺增生症(BPH)、腹部脂肪积聚、代谢综合征、2型糖尿病、癌症恶病质、阿尔茨海默病、肌肉萎缩症、认知能力下降、性功能障碍、睡眠呼吸暂停、抑郁症、早发性卵巢衰竭和自身免疫疾病,可单独使用或与其他活性剂联合使用。